The DOI matches its Crossref record; 301 of the 301 references it cites were found in a registry or an index.
NK cells and ILCs in tumor immunotherapy
Open accessAbstract
Cells of the innate immunity play an important role in tumor immunotherapy. Thus, NK cells can control tumor growth and metastatic spread. Thanks to their strong cytolytic activity against tumors, different approaches have been developed for exploiting/harnessing their function in patients with leukemia or solid tumors. Pioneering trials were based on the adoptive transfer of autologous NK cell-enriched cell populations that were expanded in vitro and co-infused with IL-2. Although relevant results were obtained in patients with advanced melanoma, the effect was mostly limited to certain metastatic localizations, particularly to the lung. In addition, the severe IL-2-related toxicity and the preferential IL-2-induced expansion of Treg limited this type of approach. This limitation may be overcome by the use of IL-15, particularly of modified IL-15 molecules to improve its half-life and optimize the biological effects. Other approaches to harness NK cell function include stimulation via TLR, the use of bi- and tri-specific NK cell engagers (BiKE and TriKE) linking activating NK receptors (e.g. CD16) to tumor-associated antigens and even incorporating an IL-15 moiety (TriKE). As recently shown, in tumor patients, NK cells may also express inhibitory checkpoints, primarily PD-1. Accordingly, the therapeutic use of checkpoint inhibitors may unleash NK cells against PD-L1+ tumors. This effect may be predominant and crucial in tumors that have lost HLA cl-I expression, thus resulting “invisible” to T lymphocytes. Additional approaches in which NK cells may represent an important tool for cancer therapy, are to exploit the unique properties of the “adaptive” NK cells. These CD57+ NKG2C+ cells, despite their mature stage and a potent cytolytic activity, maintain a strong proliferating capacity. This property revealed to be crucial in hematopoietic stem cell transplantation (HSCT), particularly in the haplo-HSCT setting, to cure high-risk leukemias. T depleted haplo-HSCT (e.g. from one of the parents) allowed to save the life of thousands of patients lacking a HLA-compatible donor. In this setting, NK cells have been shown to play an essential role against leukemia cells and infections. Another major advance is represented by chimeric antigen receptor (CAR)-engineered NK cells. CAR-NK, different from CAR-T cells, may be obtained from allogeneic donors since they do not cause GvHD. Accordingly, they may represent “off-the-shelf” products to promptly treat tumor patients, with affordable costs. Different from NK cells, helper ILC (ILC1, ILC2 and ILC3), the innate counterpart of T helper cell subsets, remain rather ambiguous with respect to their anti-tumor activity. A possible exception is represented by a subset of ILC3: their frequency in peri-tumoral tissues in patients with NSCLC directly correlates with a better prognosis, possibly reflecting their ability to contribute to the organization of tertiary lymphoid structures, an important site of T cell-mediated anti-tumor responses. It is conceivable that innate immunity may significantly contribute to the major advances that immunotherapy has ensured and will continue to ensure to the cure of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“Immature myeloid cells and tumor associated macrophages (TAM) can polarize a Th2 response and/or produce suppressive factors such as IL-10, TGF-β and reactive oxygen species (ROS) (Gabrilovich et al., 2012).”
BackgroundEffectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., et al. (2002) · Science · doi:10.1126/science.1068440 · Cited by 3,380
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 2,999
Innate or adaptive immunity? The example of natural killer cells
Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011) · Science · doi:10.1126/science.1198687 · Cited by 2,824
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704093161501 · Cited by 2,735
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709919 · Cited by 2,688 · cited 2×
“neurotoxicity, have been observed in patients given CAR-T cells (Maude et al., 2018; Neelapu et al., 2017; Park et al., 2018), but not when”
BackgroundHematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522 · cited 1×
“Allogeneic HSCT represents a life-saving therapy for patients with high-risk acute leukemia (Copelan, 2006).”
BackgroundInnate lymphoid cells — a proposal for uniform nomenclature
Spits, H., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J. P., Eberl, G., Koyasu, S., Locksley, R. M., McKenzie, A. N. J., Mebius, R. E., et al. (2013) · Nature Reviews Immunology · doi:10.1038/nri3365 · Cited by 2,389
HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C
Braud, V. M., Allan, D. S. J., O'Callaghan, C. A., Söderström, K., D'Andrea, A., Ogg, G. S., Lazetic, S., Young, N. T., Bell, J. I., Phillips, J. H., et al. (1998) · Nature · doi:10.1038/35869 · Cited by 2,227
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910607 · Cited by 2,217
Innate Lymphoid Cells: 10 Years On
Vivier, E., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J. P., Eberl, G., Koyasu, S., Locksley, R. M., McKenzie, A. N. J., Mebius, R. E., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.017 · Cited by 2,124
Innate production of TH2 cytokines by adipose tissue-associated c-Kit+Sca-1+ lymphoid cells
Moro, K., Yamada, T., Tanabe, M., Takeuchi, T., Ikawa, T., Kawamoto, H., Furusawa, J.-I., Ohtani, M., Fujii, H., & Koyasu, S. (2010) · Nature · doi:10.1038/nature08636 · Cited by 1,992
Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity
Neill, D. R., Wong, S. H., Bellosi, A., Flynn, R. J., Daly, M., Langford, T. K. A., Bucks, C., Kane, C. M., Fallon, P. G., Pannell, R., et al. (2010) · Nature · doi:10.1038/nature08900 · Cited by 1,938
Caligiuri, M. A. (2008) · Blood · doi:10.1182/blood-2007-09-077438 · Cited by 1,905
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,903
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Böttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857
Activating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated Cytolysis
Moretta, A., Bottino, C., Vitale, M., Pende, D., Cantoni, C., Mingari, M. C., Biassoni, R., & Moretta, L. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.197 · Cited by 1,778
Self-citationThe biology of innate lymphoid cells
Artis, D., & Spits, H. (2015) · Nature · doi:10.1038/nature14189 · Cited by 1,634
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,592
Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus
Monticelli, L. A., Sonnenberg, G. F., Abt, M. C., Alenghat, T., Ziegler, C. G. K., Doering, T. A., Angelosanto, J. M., Laidlaw, B. J., Yang, C. Y., Sathaliyawala, T., et al. (2011) · Nature Immunology · doi:10.1038/ni.2131 · Cited by 1,321
Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus
Monticelli (2011) · PubMed · doi:10.1031/ni.2131 · Cited by 1,286
A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity
Cella, M., Fuchs, A., Vermi, W., Facchetti, F., Otero, K., Lennerz, J. K. M., Doherty, J. M., Mills, J. C., & Colonna, M. (2009) · Nature · doi:10.1038/nature07537 · Cited by 1,251
Six-of-the-best: unique contributions of γδ T cells to immunology
Vantourout, P., & Hayday, A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3384 · Cited by 1,232 · cited 1×
“Also the high number γδT cells infused with the graft (median dose 8.1 × 106/kg), may greatly contribute to the killing of residual leukemia blasts escaping the conditioning regimen and to protect patients against infections (Airoldi et al., 2015; Braza and Klein, 2013; Vantourout and Hayday, 2013).”
BackgroundInfluentialInterferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Castro, F., Cardoso, A. P., Gonçalves, R. M., Serre, K., & Oliveira, M. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00847 · Cited by 1,224
André, P., Denis, C., Soulas, C., Bourbon-Caillet, C., Lopez, J., Arnoux, T., Bléry, M., Bonnafous, C., Gauthier, L., Morel, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.014 · Cited by 1,221
MHC class I molecules and kirs in human history, health and survival
Parham, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1570 · Cited by 1,203
Imai, K., Matsuyama, S., Miyake, S., Suga, K., & Nakachi, K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03231-1 · Cited by 1,190
Aversa, F., Tabilio, A., Velardi, A., Cunningham, I., Terenzi, A., Falzetti, F., Ruggeri, L., Barbabietola, G., Aristei, C., Latini, P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810223391702 · Cited by 1,168
Natural Killer Cells: Development, Maturation, and Clinical Utilization
Abel, A. M., Yang, C., Thakar, M. S., & Malarkannan, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01869 · Cited by 1,150
Systemically dispersed innate IL-13–expressing cells in type 2 immunity
Price, A. E., Liang, H.-E., Sullivan, B. M., Reinhardt, R. L., Eisley, C. J., Erle, D. J., & Locksley, R. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003988107 · Cited by 1,131
Zhang, Q., Bi, J., Zheng, X., Chen, Y., Wang, H., Wu, W., Wang, Z., Wu, Q., Peng, H., Wei, H., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0132-0 · Cited by 1,122
HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. Registry
Gragert, L., Eapen, M., Williams, E., Freeman, J., Spellman, S., Baitty, R., Hartzman, R., Rizzo, J. D., Horowitz, M., Confer, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmsa1311707 · Cited by 1,103
Satoh-Takayama, N., Vosshenrich, C. A. J., Lesjean-Pottier, S., Sawa, S., Lochner, M., Rattis, F., Mention, J.-J., Thiam, K., Cerf-Bensussan, N., Mandelboim, O., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.11.001 · Cited by 1,095
Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology
Buonocore, S., Ahern, P. P., Uhlig, H. H., Ivanov, I. I., Littman, D. R., Maloy, K. J., & Powrie, F. (2010) · Nature · doi:10.1038/nature08949 · Cited by 1,067
Human Diversity in Killer Cell Inhibitory Receptor Genes
Uhrberg, M., Valiante, N. M., Shum, B. P., Shilling, H. G., Lienert-Weidenbach, K., Corliss, B., Tyan, D., Lanier, L. L., & Parham, P. (1997) · Immunity · doi:10.1016/s1074-7613(00)80394-5 · Cited by 1,059
HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A
Lee, N., Llano, M., Carretero, M., Ishitani, A., Navarro, F., López-Botet, M., & Geraghty, D. E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5199 · Cited by 1,053
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
Barry, K. C., Hsu, J., Broz, M. L., Cueto, F. J., Binnewies, M., Combes, A. J., Nelson, A. E., Loo, K., Kumar, R., Rosenblum, M. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0085-8 · Cited by 1,021
KIR: Diverse, Rapidly Evolving Receptors of Innate and Adaptive Immunity
Vilches, C., & Parham, P. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.092501.134942 · Cited by 986
Ghiringhelli, F., Ménard, C., Terme, M., Flament, C., Taieb, J., Chaput, N., Puig, P. E., Novault, S., Escudier, B., Vivier, E., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051511 · Cited by 949
Romee, R., Rosario, M., Berrien-Elliott, M. M., Wagner, J. A., Jewell, B. A., Schappe, T., Leong, J. W., Abdel-Latif, S., Schneider, S. E., Willey, S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2341 · Cited by 942
LAG-3, a novel lymphocyte activation gene closely related to CD4.
Triebel, F., Jitsukawa, S., Baixeras, E., Roman-Roman, S., Genevee, C., Viegas-Pequignot, E., & Hercend, T. (1990) · The Journal of experimental medicine · doi:10.1084/jem.171.5.1393 · Cited by 925
Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells
Lanier, L. L., Corliss, B. C., Wu, J., Leong, C., & Phillips, J. H. (1998) · Nature · doi:10.1038/35642 · Cited by 904
Innate lymphoid cells: A new paradigm in immunology
Eberl, G., Colonna, M., Di Santo, J. P., & McKenzie, A. N. J. (2015) · Science · doi:10.1126/science.aaa6566 · Cited by 878
RECEPTORS FOR HLA CLASS-I MOLECULES IN HUMAN NATURAL KILLER CELLS
Moretta, A., Bottino, C., Vitale, M., Pende, D., Biassoni, R., Mingari, M. C., & Moretta, L. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.619 · Cited by 875
Self-citationFibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Wang, J., Sanmamed, M. F., Datar, I., Su, T. T., Ji, L., Sun, J., Chen, L., Chen, Y., Zhu, G., Yin, W., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.010 · Cited by 871
Imprint of human cytomegalovirus infection on the NK cell receptor repertoire
Gumá, M., Angulo, A., Vilches, C., Gómez-Lozano, N., Malats, N., & López-Botet, M. (2004) · Blood · doi:10.1182/blood-2004-05-2058 · Cited by 865
The Transcription Factor GATA-3 Controls Cell Fate and Maintenance of Type 2 Innate Lymphoid Cells
Hoyler, T., Klose, C. S. N., Souabni, A., Turqueti-Neves, A., Pfeifer, D., Rawlins, E. L., Voehringer, D., Busslinger, M., & Diefenbach, A. (2012) · Immunity · doi:10.1016/j.immuni.2012.06.020 · Cited by 852
Regulation of Ligands for the NKG2D Activating Receptor
Raulet, D. H., Gasser, S., Gowen, B. G., Deng, W., & Jung, H. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095951 · Cited by 848
Sanos, S. L., Bui, V. L., Mortha, A., Oberle, K., Heners, C., Johner, C., & Diefenbach, A. (2009) · Nature Immunology · doi:10.1038/ni.1684 · Cited by 847
Imai, C., Mihara, K., Andreansky, M., Nicholson, I. C., Pui, C.-H., Geiger, T. L., & Campana, D. (2004) · Leukemia · doi:10.1038/sj.leu.2403302 · Cited by 840
Liu, E., Tong, Y., Dotti, G., Shaim, H., Savoldo, B., Mukherjee, M., Orange, J., Wan, X., Lu, X., Reynolds, A., et al. (2018) · Leukemia · doi:10.1038/leu.2017.226 · Cited by 824
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99317 · Cited by 817
Benson, D. M., Bakan, C. E., Mishra, A., Hofmeister, C. C., Efebera, Y., Becknell, B., Baiocchi, R. A., Zhang, J., Yu, J., Smith, M. K., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271874 · Cited by 807
Pende, D., Parolini, S., Pessino, A., Sivori, S., Augugliaro, R., Morelli, L., Marcenaro, E., Accame, L., Malaspina, A., Biassoni, R., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1505 · Cited by 798
Self-citationSchlums, H., Cichocki, F., Tesi, B., Theorell, J., Beziat, V., Holmes, T. D., Han, H., Chiang, S. C. C., Foley, B., Mattsson, K., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.02.008 · Cited by 787
Vitale, M., Bottino, C., Sivori, S., Sanseverino, L., Castriconi, R., Marcenaro, E., Augugliaro, R., Moretta, L., & Moretta, A. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.12.2065 · Cited by 748
Self-citationRosenberg, S. A., Mulé, J. J., Spiess, P. J., Reichert, C. M., & Schwarz, S. L. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.5.1169 · Cited by 745
Castriconi, R., Cantoni, C., Della Chiesa, M., Vitale, M., Marcenaro, E., Conte, R., Biassoni, R., Bottino, C., Moretta, L., & Moretta, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730640100 · Cited by 726
Self-citationCEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Huang, Y.-H., Zhu, C., Kondo, Y., Anderson, A. C., Gandhi, A., Russell, A., Dougan, S. K., Petersen, B.-S., Melum, E., Pertel, T., et al. (2015) · Nature · doi:10.1038/nature13848 · Cited by 717
Coca, S., Perez-Piqueras, J., Martinez, D., Colmenarejo, A., Saez, M. A., Vallejo, C., Martos, J. A., & Moreno, M. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970615)79:12<2320::aid-cncr5>3.0.co;2-p · Cited by 716
Brandt, C. S., Baratin, M., Yi, E. C., Kennedy, J., Gao, Z., Fox, B., Haldeman, B., Ostrander, C. D., Kaifu, T., Chabannon, C., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090681 · Cited by 706
Mebius, R. E., Rennert, P., & Weissman, I. L. (1997) · Immunity · doi:10.1016/s1074-7613(00)80371-4 · Cited by 693
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Denman, C. J., Senyukov, V. V., Somanchi, S. S., Phatarpekar, P. V., Kopp, L. M., Johnson, J. L., Singh, H., Hurton, L., Maiti, S. N., Huls, M. H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030264 · Cited by 683
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
Gao, Y., Souza-Fonseca-Guimaraes, F., Bald, T., Ng, S. S., Young, A., Ngiow, S. F., Rautela, J., Straube, J., Waddell, N., Blake, S. J., et al. (2017) · Nature Immunology · doi:10.1038/ni.3800 · Cited by 654
Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding
Salih, H. R., Rammensee, H.-G., & Steinle, A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.8.4098 · Cited by 643
DNAM-1, A Novel Adhesion Molecule Involved in the Cytolytic Function of T Lymphocytes
Shibuya, A., Campbell, D., Hannum, C., Yssel, H., Franz-Bacon, K., McClanahan, T., Kitamura, T., Nicholl, J., Sutherland, G. R., Lanier, L. L., et al. (1996) · Immunity · doi:10.1016/s1074-7613(00)70060-4 · Cited by 641
The Transcription Factor GATA3 Is Essential for the Function of Human Type 2 Innate Lymphoid Cells
Mjösberg, J., Bernink, J., Golebski, K., Karrich, J. J., Peters, C. P., Blom, B., te Velde, A. A., Fokkens, W. J., van Drunen, C. M., & Spits, H. (2012) · Immunity · doi:10.1016/j.immuni.2012.08.015 · Cited by 636
Foley, B., Cooley, S., Verneris, M. R., Pitt, M., Curtsinger, J., Luo, X., Lopez-Vergès, S., Lanier, L. L., Weisdorf, D., & Miller, J. S. (2012) · Blood · doi:10.1182/blood-2011-10-386995 · Cited by 630
Ruggeri, L., Mancusi, A., Capanni, M., Urbani, E., Carotti, A., Aloisi, T., Stern, M., Pende, D., Perruccio, K., Burchielli, E., et al. (2007) · Blood · doi:10.1182/blood-2006-07-038687 · Cited by 616
Self-citationvon Stackelberg, A., Locatelli, F., Zugmaier, G., Handgretinger, R., Trippett, T. M., Rizzari, C., Bader, P., O’Brien, M. M., Brethon, B., Bhojwani, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3301 · Cited by 614
Self-citationNKG2D Receptor and Its Ligands in Host Defense
Lanier, L. L. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0098 · Cited by 599 · cited 3×
“The presence of a positively-charged aminoacid in the NCR transmembrane domain allows NCR association with ITAM-bearing adaptor proteins, in particular CD3-ζ and/or FcεRI-γ (for NKp30 and NKp46) and KARAP/DAP12 (for NKp44), that are essential for the transduction of positive signals inside NK cells.”
BackgroundExpansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
Fujisaki, H., Kakuda, H., Shimasaki, N., Imai, C., Ma, J., Lockey, T., Eldridge, P., Leung, W. H., & Campana, D. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3712 · Cited by 595
Cooley, S., Weisdorf, D. J., Guethlein, L. A., Klein, J. P., Wang, T., Le, C. T., Marsh, S. G. E., Geraghty, D., Spellman, S., Haagenson, M. D., et al. (2010) · Blood · doi:10.1182/blood-2010-05-283051 · Cited by 591
Prognostic value of intratumoral natural killer cells in gastric carcinoma
Ishigami, S., Natsugoe, S., Tokuda, K., Nakajo, A., Che, X., Iwashige, H., Aridome, K., Hokita, S., & Aikou, T. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000201)88:3<577::aid-cncr13>3.0.co;2-v · Cited by 586
Pessino, A., Sivori, S., Bottino, C., Malaspina, A., Morelli, L., Moretta, L., Biassoni, R., & Moretta, A. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.5.953 · Cited by 579
Self-citationHuman Tumor-Derived Exosomes Down-Modulate NKG2D Expression
Clayton, A., Mitchell, J. P., Court, J., Linnane, S., Mason, M. D., & Tabi, Z. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7249 · Cited by 574
Human NK cells: surface receptors, inhibitory checkpoints, and translational applications
Sivori, S., Vacca, P., Del Zotto, G., Munari, E., Mingari, M. C., & Moretta, L. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0206-4 · Cited by 555
Self-citationp46, a Novel Natural Killer Cell–specific Surface Molecule That Mediates Cell Activation
Sivori, S., Vitale, M., Morelli, L., Sanseverino, L., Augugliaro, R., Bottino, C., Moretta, L., & Moretta, A. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.7.1129 · Cited by 554
Self-citationExploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’
Levin, A. M., Bates, D. L., Ring, A. M., Krieg, C., Lin, J. T., Su, L., Moraga, I., Raeber, M. E., Bowman, G. R., Novick, P., et al. (2012) · Nature · doi:10.1038/nature10975 · Cited by 552
Lee, J., Zhang, T., Hwang, I., Kim, A., Nitschke, L., Kim, M., Scott, J. M., Kamimura, Y., Lanier, L. L., & Kim, S. (2015) · Immunity · doi:10.1016/j.immuni.2015.02.013 · Cited by 552
Monticelli, L. A., Osborne, L. C., Noti, M., Tran, S. V., Zaiss, D. M. W., & Artis, D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1509070112 · Cited by 530
Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma
Platonova, S., Cherfils-Vicini, J., Damotte, D., Crozet, L., Vieillard, V., Validire, P., André, P., Dieu-Nosjean, M.-C., Alifano, M., Régnard, J.-F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4179 · Cited by 512
Costello, R. T., Sivori, S., Marcenaro, E., Lafage-Pochitaloff, M., Mozziconacci, M.-J., Reviron, D., Gastaut, J.-A., Pende, D., Olive, D., & Moretta, A. (2002) · Blood · doi:10.1182/blood.v99.10.3661 · Cited by 500
Self-citationX-Linked Lymphoproliferative Disease
Parolini, S., Bottino, C., Falco, M., Augugliaro, R., Giliani, S., Franceschini, R., Ochs, H. D., Wolf, H., Bonnefoy, J.-Y., Biassoni, R., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.3.337 · Cited by 477
Self-citationVillegas, F. R., Coca, S., Villarrubia, V. G., Jiménez, R., Chillón, M. J., Jareño, J., Zuil, M., & Callol, L. (2002) · Lung Cancer · doi:10.1016/s0169-5002(01)00292-6 · Cited by 467
Treatment of patients with advanced cancer with the natural killer cell line NK-92
Tonn, T., Schwabe, D., Klingemann, H. G., Becker, S., Esser, R., Koehl, U., Suttorp, M., Seifried, E., Ottmann, O. G., & Bug, G. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2013.06.017 · Cited by 467
Pesce, S., Greppi, M., Tabellini, G., Rampinelli, F., Parolini, S., Olive, D., Moretta, L., Moretta, A., & Marcenaro, E. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.04.025 · Cited by 465
Self-citationSivori, S., Falco, M., Chiesa, M. D., Carlomagno, S., Vitale, M., Moretta, L., & Moretta, A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403744101 · Cited by 455
Self-citationExpansion of CD94/NKG2C+ NK cells in response to human cytomegalovirus-infected fibroblasts
Gumá, M., Budt, M., Sáez, A., Brckalo, T., Hengel, H., Angulo, A., & López-Botet, M. (2006) · Blood · doi:10.1182/blood-2005-09-3682 · Cited by 449
Moretta, A., Sivori, S., Vitale, M., Pende, D., Morelli, L., Augugliaro, R., Bottino, C., & Moretta, L. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.3.875 · Cited by 447
Self-citationHsu, K. C., Chida, S., Geraghty, D. E., & Dupont, B. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.19004.x · Cited by 443
NK cells and type 1 innate lymphoid cells: partners in host defense
Spits, H., Bernink, J. H., & Lanier, L. (2016) · Nature Immunology · doi:10.1038/ni.3482 · Cited by 443
Chu, J., Deng, Y., Benson, D. M., He, S., Hughes, T., Zhang, J., Peng, Y., Mao, H., Yi, L., Ghoshal, K., et al. (2014) · Leukemia · doi:10.1038/leu.2013.279 · Cited by 439
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity
Gauthier, L., Morel, A., Anceriz, N., Rossi, B., Blanchard-Alvarez, A., Grondin, G., Trichard, S., Cesari, C., Sapet, M., Bosco, F., et al. (2019) · Cell · doi:10.1016/j.cell.2019.04.041 · Cited by 439
TIGIT and CD 96: new checkpoint receptor targets for cancer immunotherapy
Dougall, W. C., Kurtulus, S., Smyth, M. J., & Anderson, A. C. (2017) · Immunological Reviews · doi:10.1111/imr.12518 · Cited by 435
Simoni, Y., Fehlings, M., Kløverpris, H. N., McGovern, N., Koo, S.-L., Loh, C. Y., Lim, S., Kurioka, A., Fergusson, J. R., Tang, C.-L., et al. (2017) · Immunity · doi:10.1016/j.immuni.2016.11.005 · Cited by 431
Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
da Silva, I. P., Gallois, A., Jimenez-Baranda, S., Khan, S., Anderson, A. C., Kuchroo, V. K., Osman, I., & Bhardwaj, N. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0171 · Cited by 424
Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells
Hammer, Q., Rückert, T., Borst, E. M., Dunst, J., Haubner, A., Durek, P., Heinrich, F., Gasparoni, G., Babic, M., Tomic, A., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0082-6 · Cited by 423
Self-citationSivori, S., Pende, D., Bottino, C., Marcenaro, E., Pessino, A., Biassoni, R., Moretta, L., & Moretta, A. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199905)29:05<1656::aid-immu1656>3.0.co;2-1 · Cited by 422
Self-citationSzczepanski, M. J., Szajnik, M., Welsh, A., Whiteside, T. L., & Boyiadzis, M. (2011) · Haematologica · doi:10.3324/haematol.2010.039743 · Cited by 422
Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors
Melaiu, O., Lucarini, V., Cifaldi, L., & Fruci, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03038 · Cited by 419
Romee, R., Cooley, S., Berrien-Elliott, M. M., Westervelt, P., Verneris, M. R., Wagner, J. E., Weisdorf, D. J., Blazar, B. R., Ustun, C., DeFor, T. E., et al. (2018) · Blood · doi:10.1182/blood-2017-12-823757 · Cited by 409
Tang, X., Yang, L., Li, Z., Nalin, A. P., Dai, H., Xu, T., Yin, J., You, F., Zhu, M., Shen, W., et al. (2018) · Europe PMC (PubMed Central) · Cited by 406
Chiesa, M. D., Carlomagno, S., Frumento, G., Balsamo, M., Cantoni, C., Conte, R., Moretta, L., Moretta, A., & Vitale, M. (2006) · Blood · doi:10.1182/blood-2006-03-006700 · Cited by 399
Self-citationCharych, D. H., Hoch, U., Langowski, J. L., Lee, S. R., Addepalli, M. K., Kirk, P. B., Sheng, D., Liu, X., Sims, P. W., VanderVeen, L. A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1631 · Cited by 398
Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities
Hu, W., Wang, G., Huang, D., Sui, M., & Xu, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01205 · Cited by 398
Vallera, D. A., Felices, M., McElmurry, R., McCullar, V., Zhou, X., Schmohl, J. U., Zhang, B., Lenvik, A. J., Panoskaltsis-Mortari, A., Verneris, M. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2710 · Cited by 391
Pende, D., Falco, M., Vitale, M., Cantoni, C., Vitale, C., Munari, E., Bertaina, A., Moretta, F., Del Zotto, G., Pietra, G., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01179 · Cited by 389
Self-citationErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma
Zhang, C., Burger, M. C., Jennewein, L., Genßler, S., Schönfeld, K., Zeiner, P., Hattingen, E., Harter, P. N., Mittelbronn, M., Tonn, T., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv375 · Cited by 388
Location and cellular stages of natural killer cell development
Yu, J., Freud, A. G., & Caligiuri, M. A. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.07.005 · Cited by 387
Pende, D., Marcenaro, S., Falco, M., Martini, S., Bernardo, M. E., Montagna, D., Romeo, E., Cognet, C., Martinetti, M., Maccario, R., et al. (2009) · Blood · doi:10.1182/blood-2008-06-164103 · Cited by 378
Self-citationDisulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands
Kaiser, B. K., Yim, D., Chow, I.-T., Gonzalez, S., Dai, Z., Mann, H. H., Strong, R. K., Groh, V., & Spies, T. (2007) · Nature · doi:10.1038/nature05768 · Cited by 377
Pogge von Strandmann, E., Simhadri, V. R., von Tresckow, B., Sasse, S., Reiners, K. S., Hansen, H. P., Rothe, A., Böll, B., Simhadri, V. L., Borchmann, P., et al. (2007) · Immunity · doi:10.1016/j.immuni.2007.10.010 · Cited by 374
Negative signaling by inhibitory receptors: the NK cell paradigm
Long, E. O. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00660.x · Cited by 370
The Natural Cytotoxicity Receptors in Health and Disease
Barrow, A. D., Martin, C. J., & Colonna, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00909 · Cited by 370
Liu, Y., Cheng, Y., Xu, Y., Wang, Z., Du, X., Li, C., Peng, J., Gao, L., Liang, X., & Ma, C. (2017) · Oncogene · doi:10.1038/onc.2017.209 · Cited by 366
Leishmania lipophosphoglycan (LPG) activates NK cells through toll-like receptor-2
Becker, I., Salaiza, N., Aguirre, M., Delgado, J., Carrillo-Carrasco, N., Kobeh, L. G., Ruiz, A., Cervantes, R., Torres, A. P., Cabrera, N., et al. (2003) · Molecular and Biochemical Parasitology · doi:10.1016/s0166-6851(03)00160-9 · Cited by 353
Chalifour, A., Jeannin, P., Gauchat, J.-F., Blaecke, A., Malissard, M., N'Guyen, T., Thieblemont, N., & Delneste, Y. (2004) · Blood · doi:10.1182/blood-2003-08-2820 · Cited by 351
Ciurea, S. O., Schafer, J. R., Bassett, R., Denman, C. J., Cao, K., Willis, D., Rondon, G., Chen, J., Soebbing, D., Kaur, I., et al. (2017) · Blood · doi:10.1182/blood-2017-05-785659 · Cited by 345
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
Delahaye, N. F., Rusakiewicz, S., Martins, I., Ménard, C., Roux, S., Lyonnet, L., Paul, P., Sarabi, M., Chaput, N., Semeraro, M., et al. (2011) · Nature Medicine · doi:10.1038/nm.2366 · Cited by 341
Han, J., Chu, J., Keung Chan, W., Zhang, J., Wang, Y., Cohen, J. B., Victor, A., Meisen, W. H., Kim, S.-H., Grandi, P., et al. (2015) · Scientific Reports · doi:10.1038/srep11483 · Cited by 340
Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity
Balsamo, M., Scordamaglia, F., Pietra, G., Manzini, C., Cantoni, C., Boitano, M., Queirolo, P., Vermi, W., Facchetti, F., Moretta, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906481106 · Cited by 330
Self-citationHepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO
Li, T., Yang, Y., Hua, X., Wang, G., Liu, W., Jia, C., Tai, Y., Zhang, Q., & Chen, G. (2012) · Cancer Letters · doi:10.1016/j.canlet.2011.12.020 · Cited by 328
Pietra, G., Manzini, C., Rivara, S., Vitale, M., Cantoni, C., Petretto, A., Balsamo, M., Conte, R., Benelli, R., Minghelli, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2544 · Cited by 324
Self-citationLocatelli, F., Merli, P., Pagliara, D., Li Pira, G., Falco, M., Pende, D., Rondelli, R., Lucarelli, B., Brescia, L. P., Masetti, R., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779769 · Cited by 316
Self-citationVari, F., Arpon, D., Keane, C., Hertzberg, M. S., Talaulikar, D., Jain, S., Cui, Q., Han, E., Tobin, J., Bird, R., et al. (2018) · Blood · doi:10.1182/blood-2017-07-796342 · Cited by 313
PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
Beldi-Ferchiou, A., Lambert, M., Dogniaux, S., Vély, F., Vivier, E., Olive, D., Dupuy, S., Levasseur, F., Zucman, D., Lebbé, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12150 · Cited by 312
TLR7/8-Mediated Activation of Human NK Cells Results in Accessory Cell-Dependent IFN-γ Production
Hart, O. M., Athie-Morales, V., O’Connor, G. M., & Gardiner, C. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1636 · Cited by 310
Ulbrecht, M., Martinozzi, S., Grzeschik, M., Hengel, H., Ellwart, J. W., Pla, M., & Weiss, E. H. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.10.5019 · Cited by 310
Bottino, C., Falco, M., Parolini, S., Marcenaro, E., Augugliaro, R., Sivori, S., Landi, E., Biassoni, R., Notarangelo, L. D., Moretta, L., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.3.235 · Cited by 310
Self-citationEducation of human natural killer cells by activating killer cell immunoglobulin-like receptors
Fauriat, C., Ivarsson, M. A., Ljunggren, H.-G., Malmberg, K.-J., & Michaëlsson, J. (2010) · Blood · doi:10.1182/blood-2009-09-245746 · Cited by 305
Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
Rusakiewicz, S., Semeraro, M., Sarabi, M., Desbois, M., Locher, C., Mendez, R., Vimond, N., Concha, A., Garrido, F., Isambert, N., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0371 · Cited by 305
Sun, H., Huang, Q., Huang, M., Wen, H., Lin, R., Zheng, M., Qu, K., Li, K., Wei, H., Xiao, W., et al. (2019) · Hepatology · doi:10.1002/hep.30347 · Cited by 300
Balsamo, M., Manzini, C., Pietra, G., Raggi, F., Blengio, F., Mingari, M. C., Varesio, L., Moretta, L., Bosco, M. C., & Vitale, M. (2013) · European Journal of Immunology · doi:10.1002/eji.201343448 · Cited by 282
Self-citationUnifying concepts of MHC-dependent natural killer cell education
Elliott, J. M., & Yokoyama, W. M. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.06.001 · Cited by 279
Cutting Edge: Antibody-Dependent Memory-like NK Cells Distinguished by FcRγ Deficiency
Zhang, T., Scott, J. M., Hwang, I., & Kim, S. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203034 · Cited by 271
NCR+ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures
Carrega, P., Loiacono, F., Di Carlo, E., Scaramuccia, A., Mora, M., Conte, R., Benelli, R., Spaggiari, G. M., Cantoni, C., Campana, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9280 · Cited by 271
Self-citationGleason, M. K., Ross, J. A., Warlick, E. D., Lund, T. C., Verneris, M. R., Wiernik, A., Spellman, S., Haagenson, M. D., Lenvik, A. J., Litzow, M. R., et al. (2014) · Blood · doi:10.1182/blood-2013-10-533398 · Cited by 266
Uherek, C., Tonn, T., Uherek, B., Becker, S., Schnierle, B., Klingemann, H.-G., & Wels, W. (2002) · Blood · doi:10.1182/blood.v100.4.1265.h81602001265_1265_1273 · Cited by 262
Olcese, L., Cambiaggi, A., Semenzato, G., Bottino, C., Moretta, A., & Vivier, E. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.11.5083 · Cited by 262
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
Curti, A., Trabanelli, S., Salvestrini, V., Baccarani, M., & Lemoli, R. M. (2009) · Blood · doi:10.1182/blood-2008-07-144485 · Cited by 259
Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
Mehta, R. S., & Rezvani, K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00283 · Cited by 259
Della Chiesa, M., Falco, M., Podestà, M., Locatelli, F., Moretta, L., Frassoni, F., & Moretta, A. (2012) · Blood · doi:10.1182/blood-2011-08-372003 · Cited by 254
Self-citationAPC-Independent Activation of NK Cells by the Toll-Like Receptor 3 Agonist Double-Stranded RNA
Schmidt, K. N., Leung, B., Kwong, M., Zarember, K. A., Satyal, S., Navas, T. A., Wang, F., & Godowski, P. J. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.1.138 · Cited by 242
Hoskin, D., Mader, J., Furlong, S., Conrad, D., & Blay, J. (2008) · International Journal of Oncology · doi:10.3892/ijo.32.3.527 · Cited by 242
Human NK cells can control CMV infection in the absence of T cells
Kuijpers, T. W., Baars, P. A., Dantin, C., van den Burg, M., van Lier, R. A. W., & Roosnek, E. (2008) · Blood · doi:10.1182/blood-2008-05-157354 · Cited by 241
Targeting natural killer cells in solid tumors
Habif, G., Crinier, A., André, P., Vivier, E., & Narni-Mancinelli, E. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0224-2 · Cited by 241
Reiners, K. S., Topolar, D., Henke, A., Simhadri, V. R., Kessler, J., Sauer, M., Bessler, M., Hansen, H. P., Tawadros, S., Herling, M., et al. (2013) · Blood · doi:10.1182/blood-2013-01-476606 · Cited by 239
NKG2D and its ligands in cancer
Dhar, P., & Wu, J. D. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.02.004 · Cited by 239
Airoldi, I., Bertaina, A., Prigione, I., Zorzoli, A., Pagliara, D., Cocco, C., Meazza, R., Loiacono, F., Lucarelli, B., Bernardo, M. E., et al. (2015) · Blood · doi:10.1182/blood-2014-09-599423 · Cited by 238
Self-citationHilpert, J., Grosse-Hovest, L., Grünebach, F., Buechele, C., Nuebling, T., Raum, T., Steinle, A., & Salih, H. R. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200796 · Cited by 238
Gleason, M. K., Verneris, M. R., Todhunter, D. A., Zhang, B., McCullar, V., Zhou, S. X., Panoskaltsis-Mortari, A., Weiner, L. M., Vallera, D. A., & Miller, J. S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0692 · Cited by 238
Pyo, C.-W., Guethlein, L. A., Vu, Q., Wang, R., Abi-Rached, L., Norman, P. J., Marsh, S. G. E., Miller, J. S., Parham, P., & Geraghty, D. E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015115 · Cited by 236
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis
Trabanelli, S., Chevalier, M. F., Martinez-Usatorre, A., Gomez-Cadena, A., Salomé, B., Lecciso, M., Salvestrini, V., Verdeil, G., Racle, J., Papayannidis, C., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00678-2 · Cited by 232
Stringaris, K., Sekine, T., Khoder, A., Alsuliman, A., Razzaghi, B., Sargeant, R., Pavlu, J., Brisley, G., de Lavallade, H., Sarvaria, A., et al. (2014) · Haematologica · doi:10.3324/haematol.2013.087536 · Cited by 231
Antibody‐dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells
Ochoa, M. C., Minute, L., Rodriguez, I., Garasa, S., Perez‐Ruiz, E., Inogés, S., Melero, I., & Berraondo, P. (2017) · Immunology & Cell Biology · doi:10.1038/icb.2017.6 · Cited by 230
Klein Wolterink, R. G. J., Serafini, N., van Nimwegen, M., Vosshenrich, C. A. J., de Bruijn, M. J. W., Fonseca Pereira, D., Veiga Fernandes, H., Hendriks, R. W., & Di Santo, J. P. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217158110 · Cited by 226
Wiernik, A., Foley, B., Zhang, B., Verneris, M. R., Warlick, E., Gleason, M. K., Ross, J. A., Luo, X., Weisdorf, D. J., Walcheck, B., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0505 · Cited by 226
Munneke, J. M., Björklund, A. T., Mjösberg, J. M., Garming-Legert, K., Bernink, J. H., Blom, B., Huisman, C., van Oers, M. H. J., Spits, H., Malmberg, K.-J., et al. (2014) · Blood · doi:10.1182/blood-2013-11-536888 · Cited by 225
Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering
Daher, M., & Rezvani, K. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.013 · Cited by 224
Han, K.-P., Zhu, X., Liu, B., Jeng, E., Kong, L., Yovandich, J. L., Vyas, V. V., Marcus, W. D., Chavaillaz, P.-A., Romero, C. A., et al. (2011) · Cytokine · doi:10.1016/j.cyto.2011.09.028 · Cited by 223
Identification of NKp80, a novel triggering molecule expressed by human NK cells
Vitale, M., Falco, M., Castriconi, R., Parolini, S., Zambello, R., Semenzato, G., Biassoni, R., Bottino, C., Moretta, L., & Moretta, A. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200101)31:1<233::aid-immu233>3.0.co;2-4 · Cited by 223
Self-citationEisenring, M., vom Berg, J., Kristiansen, G., Saller, E., & Becher, B. (2010) · Nature Immunology · doi:10.1038/ni.1947 · Cited by 221
Romanski, A., Uherek, C., Bug, G., Seifried, E., Klingemann, H., Wels, W. S., Ottmann, O. G., & Tonn, T. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12810 · Cited by 220
ILC2-modulated T cell–to-MDSC balance is associated with bladder cancer recurrence
Chevalier, M. F., Trabanelli, S., Racle, J., Salomé, B., Cesson, V., Gharbi, D., Bohner, P., Domingos-Pereira, S., Dartiguenave, F., Fritschi, A.-S., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89717 · Cited by 220
Cichocki, F., Cooley, S., Davis, Z., DeFor, T. E., Schlums, H., Zhang, B., Brunstein, C. G., Blazar, B. R., Wagner, J., Diamond, D. J., et al. (2016) · Leukemia · doi:10.1038/leu.2015.260 · Cited by 219
Rosental, B., Brusilovsky, M., Hadad, U., Oz, D., Appel, M. Y., Afergan, F., Yossef, R., Rosenberg, L. A., Aharoni, A., Cerwenka, A., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102267 · Cited by 217
Schlecker, E., Fiegler, N., Arnold, A., Altevogt, P., Rose-John, S., Moldenhauer, G., Sucker, A., Paschen, A., von Strandmann, E. P., Textor, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3017 · Cited by 216
Xu, L., Huang, Y., Tan, L., Yu, W., Chen, D., Lu, C., He, J., Wu, G., Liu, X., & Zhang, Y. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.09.017 · Cited by 214
Müller, T., Uherek, C., Maki, G., Chow, K. U., Schimpf, A., Klingemann, H.-G., Tonn, T., & Wels, W. S. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0383-3 · Cited by 212
Sun, J. C., Lopez-Verges, S., Kim, C. C., DeRisi, J. L., & Lanier, L. L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003035 · Cited by 211
Russo, A., Oliveira, G., Berglund, S., Greco, R., Gambacorta, V., Cieri, N., Toffalori, C., Zito, L., Lorentino, F., Piemontese, S., et al. (2018) · Blood · doi:10.1182/blood-2017-05-780668 · Cited by 208
PD-1 regulates KLRG1+ group 2 innate lymphoid cells
Taylor, S., Huang, Y., Mallett, G., Stathopoulou, C., Felizardo, T. C., Sun, M.-A., Martin, E. L., Zhu, N., Woodward, E. L., Elias, M. S., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20161653 · Cited by 204
Sarhan, D., Cichocki, F., Zhang, B., Yingst, A., Spellman, S. R., Cooley, S., Verneris, M. R., Blazar, B. R., & Miller, J. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0839 · Cited by 200
Pasero, C., Gravis, G., Granjeaud, S., Guerin, M., Thomassin-Piana, J., Rocchi, P., Salem, N., Walz, J., Moretta, A., & Olive, D. (2015) · Oncotarget · doi:10.18632/oncotarget.3965 · Cited by 195
Sivori, S., Falco, M., Marcenaro, E., Parolini, S., Biassoni, R., Bottino, C., Moretta, L., & Moretta, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072065999 · Cited by 195
Self-citationEsser, R., Müller, T., Stefes, D., Kloess, S., Seidel, D., Gillies, S. D., Aperlo‐Iffland, C., Huston, J. S., Uherek, C., Schönfeld, K., et al. (2012) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01343.x · Cited by 188
PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
Pesce, S., Greppi, M., Grossi, F., Del Zotto, G., Moretta, L., Sivori, S., Genova, C., & Marcenaro, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01242 · Cited by 187
Self-citationIdentification of a cellular ligand for the natural cytotoxicity receptor NKp44
Baychelier, F., Sennepin, A., Ermonval, M., Dorgham, K., Debré, P., & Vieillard, V. (2013) · Blood · doi:10.1182/blood-2013-03-489054 · Cited by 186
IL-22 is related to development of human colon cancer by activation of STAT3
Jiang, R., Wang, H., Deng, L., Hou, J., Shi, R., Yao, M., Gao, Y., Yao, A., Wang, X., Yu, L., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-59 · Cited by 182
Dissecting CD56dim human NK cells
Moretta, L. (2010) · Blood · doi:10.1182/blood-2010-09-303057 · Cited by 181
Self-citationJiang, W., Johnson, C., Jayaraman, J., Simecek, N., Noble, J., Moffatt, M. F., Cookson, W. O., Trowsdale, J., & Traherne, J. A. (2012) · Genome Research · doi:10.1101/gr.137976.112 · Cited by 180
B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape
Pesce, S., Tabellini, G., Cantoni, C., Patrizi, O., Coltrini, D., Rampinelli, F., Matta, J., Vivier, E., Moretta, A., Parolini, S., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2014.1001224 · Cited by 178
Tumor and viral recognition by natural killer cells receptors
Arnon, T. I., Markel, G., & Mandelboim, O. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.005 · Cited by 178
Functional Differences between Human NKp44− and NKp44+ RORC+ Innate Lymphoid Cells
Hoorweg, K., Peters, C. P., Cornelissen, F., Aparicio-Domingo, P., Papazian, N., Kazemier, G., Mjösberg, J. M., Spits, H., & Cupedo, T. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00072 · Cited by 171
Not All Immune Checkpoints Are Created Equal
Linhares, A. D. S., Leitner, J. M., Grabmeier‐Pfistershammer, K., & Steinberger, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01909 · Cited by 167
Carlsten, M., Korde, N., Kotecha, R., Reger, R., Bor, S., Kazandjian, D., Landgren, O., & Childs, R. W. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1108 · Cited by 166
Searching for alternative hematopoietic stem cell donors for pediatric patients
Rocha, V., & Locatelli, F. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705963 · Cited by 165
Self-citationHaploidentical hematopoietic transplantation: current status and future perspectives
Reisner, Y., Hagin, D., & Martelli, M. F. (2011) · Blood · doi:10.1182/blood-2011-07-338822 · Cited by 165
Sarvaria, A., Jawdat, D., Madrigal, J. A., & Saudemont, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00329 · Cited by 163
Bagot, M., Porcu, P., Marie-Cardine, A., Battistella, M., William, B. M., Vermeer, M., Whittaker, S., Rotolo, F., Ram-Wolff, C., Khodadoust, M. S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30320-1 · Cited by 162
Mingari, M. C., Vitale, C., Cantoni, C., Bellomo, R., Ponte, M., Schiavetti, F., Bertone, S., Moretta, A., & Moretta, L. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270612 · Cited by 161
Self-citationNeuroblastoma-Derived TGF-β1 Modulates the Chemokine Receptor Repertoire of Human Resting NK Cells
Castriconi, R., Dondero, A., Bellora, F., Moretta, L., Castellano, A., Locatelli, F., Corrias, M. V., Moretta, A., & Bottino, C. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202693 · Cited by 159
Self-citationLocatelli, F., Pende, D., Falco, M., Chiesa, M. D., Moretta, A., & Moretta, L. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.04.009 · Cited by 159
Self-citationCurti, A., Ruggeri, L., Parisi, S., Bontadini, A., Dan, E., Motta, M. R., Rizzi, S., Trabanelli, S., Očadlíková, D., Lecciso, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1604 · Cited by 156
Cited by
Signal pathways of melanoma and targeted therapy
Guo, W., Wang, H., & Li, C. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00827-6 · Cited by 379
Peña-Romero, A. C., & Orenes-Piñero, E. (2022) · Cancers · doi:10.3390/cancers14071681 · Cited by 257
Metadata
- Authors
- Sivori, S., Pende, D., Quatrini, L., Pietra, G., Della Chiesa, M., Vacca, P., Tumino, N., Moretta, F., Mingari, M. C., Locatelli, F., & Moretta, L.
- Venue
- Molecular Aspects of Medicine
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 80
- Pages
- 100870
- ISSN
- 0098-2997 (ISSN-L)
- OpenAlex
- W3049733355
- Cited by
- 270
- References
- 301
- FWCI
- 9.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.